RPRX · ROYALTY PHARMA PLC

Back to holdings

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company has research and development funding collaboration to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases.

Close · 3M

+23.99%

Held by 1 AI ETF

LQAI0.210%

as of Jul 17

Signal performance

Each tracked ETF's moves on this stock, grouped by fund. Returns are measured from the signal date to the latest close — hypothetical, no commissions or slippage.

Buy signals3

Win rate33% (1/3)

Avg buy return+1.74%

LQAInow 0.210% of fund6 signals

LQAI · Weight increase · 2d

ROYALTY PHARMA PLC (RPRX) recently reached $58.18, sitting at 99% of its 52-week high after delivering a 30-day return of +7.8% and a 90-day return of +22.6%, a trajectory the LG-Qraft AI engine for LQAI would interpret as sustained market strength. Operating with a weekly rebalancing schedule, the Qraft AI, which guides LQAI's ~100 US large-cap core portfolio, likely identified RPRX's consistent upward price movement and strong relative performance as factors contributing to an elevated ranking within its selection universe. Despite its position near the top of its 52-week range, LQAI's AI-driven approach, positioned between broad market exposure and concentrated momentum, implies that the model values this sustained price appreciation without an exclusive tilt toward momentum, prompting the consecutive weight increases from 0.19% to 0.21% between July 15 and July 17.

weight 0.190% → 0.210% (+0.020 pp)·stock up 6.1% in the 30 days before

Jul 17·entry $58.18·now $57.30Fresh

-1.52%

since Jul 17

LQAI · New entry · 1d

weight 0 → 0.200% (new)·stock up 7.1% in the 30 days before

Jul 7·entry $57.80·now $57.30Fresh

-0.87%

since Jul 7

LQAI · Exit · 1d

RPRX is currently trading at $55.63, effectively at 100% of its 52-week high of $55.87, following a 30-day return of +12.3% and a 90-day return of +33.5%. This significant climb and position at its peak likely triggered a re-evaluation by LQAI's Qraft AI selection engine, which manages its weekly rebalancing for a portfolio of approximately 100 US large-cap core holdings. Despite LQAI's style being positioned midway between broad and concentrated momentum strategies, its AI-driven name selection appears to have detected a shift in RPRX's ranking. The model prompted the removal of RPRX from the portfolio on June 9th, reducing its weight from 0.8600% to 0.0000%, indicating that at these elevated price levels, the stock no longer met its inclusion criteria within the US large-cap universe.

weight 0.860% → 0 (exited)·stock up 9.5% in the 30 days before

Jun 9·entry $55.63·now $57.30

+2.99%

since Jun 9

LQAI · Weight decrease · 2d

RPRX's current price of $54.01, reflecting a 1-year return of +63.2% and a 90-day return of +33.7%, places it at 97% of its 52-week high. This strong appreciation positions the stock as a significant performer within the US large-cap core universe from which LQAI selects. The Qraft AI ranking engine, which guides LQAI's selection without a heavy factor tilt, initiated a consecutive weight decrease in RPRX. Following a period of sustained gains, the weight decreased from 0.83% on June 1st to 0.81% on June 2nd, occurring as RPRX's share price neared its 52-week high of $55.76. This rebalancing suggests the AI algorithm moderated exposure to a stock that had run significantly, consistent with LQAI's core large-cap style that balances growth with other considerations, positioning it midway between broad and concentrated momentum strategies.

weight 0.840% → 0.810% (-0.030 pp)·stock up 9.2% in the 30 days before

Jun 2·entry $54.01·now $57.30

+6.08%

since Jun 2

LQAI · Weight increase · 2d

The AI ETF's consecutive weighting increase in RPRX, marked by a significant jump from 0.48% to 0.82% followed by 0.84%, strongly indicates its algorithm detected a substantial positive catalyst, such as favorable clinical trial outcomes for a royalty-bearing asset or compelling fundamental news. For a retail investor, this pattern suggests the AI has identified a compelling opportunity, prompting independent due diligence on recent RPRX developments and underlying reasons for the AI's sudden conviction.

weight 0.480% → 0.840% (+0.360 pp)·stock up 9.1% in the 30 days before

May 13·entry $53.25·now $57.30Drifting

+7.60%

since May 13

LQAI · Sudden change · 1d

The AI likely significantly increased RPRX’s weight due to a recent, impactful positive catalyst such as FDA approval for a key drug Royalty Pharma holds royalties on, or an acquisition of a highly lucrative new royalty stream, which drastically improved its projected financial performance in the algorithm's model. For retail investors, this underscores that AI-managed funds swiftly rebalance based on new, material company-specific information, highlighting the need to investigate the underlying fundamental news rather than just observing portfolio changes.

weight 0.480% → 0.820% (+0.340 pp)·stock up 6.8% in the 30 days before

May 12·entry $51.70·now $57.30

+10.82%

since May 12

Sell signals show what the stock did after the AI exited. A negative number means the AI's exit was well-timed.